Recent advances in gene therapy have brought novel treatment options to multiple fields of medicine, including cancer. However, safety concerns and limited payload capacity in commonly-utilized viral vectors prevent researchers from unlocking the full potential of gene therapy. Virus-free DNA transposons, including piggyBac, have been shown to obviate these shortcomings. We have previously demonstrated the superior transposition efficiency of a modified piggyBac system in HEK293 cells. Here, we further advanced and broadened the therapeutic application of this modified piggyBac system. We demonstrated that the internal domain sequence (IDS) within the 3′ terminal repeat domain of hyperactive piggyBac (hyPB) donor vector contain dominant enhancer elements. We showed that a plasmid-free donor vector having IDS-free terminal inverted repeats in conjunction with a helper plasmid expressing Quantum pBase™ v2 form the most optimal piggyBac system, Quantum pBac™ (qPB), in T cells. We further demonstrated that T cells transfected with qPB expressing CD20/CD19 CAR outperformed cells transfected with the same donor vector but with plasmid expressing hyPB transposase in CAR-T cell production. Importantly, we showed that qPB produced mainly CD8+ CAR-T cells that are also highly represented by TSCM. These CAR-T cells effectively eliminated CD20/CD19-expressing tumor cells in vitro and in Raji-bearing immunodeficient mice. Our findings confirm that qPB is a promising virus-free vector system that is safer, and highly efficient in mediating transgene integration with the payload capacity to incorporate multiple genes.